Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort

Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM). The results from phase 2 and 3 randomized clinical trials for both drugs have showed promising outcomes. However, the highly selective p...

Full description

Bibliographic Details
Main Authors: Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani
Format: Article
Language:English
Published: IMR Press 2024-06-01
Series:Reviews in Cardiovascular Medicine
Subjects:
hypertrophic cardiomyopathy
cardiac myosin inhibitors
aficamten
mavacamten
Online Access:https://www.imrpress.com/journal/RCM/25/6/10.31083/j.rcm2506225

Internet

https://www.imrpress.com/journal/RCM/25/6/10.31083/j.rcm2506225

Similar Items